An estimated 280 epp patients in Canada. Clinuvel has gained less than 10% penetration in EU and US. Zero penetration in Australia. If approved in Canada I am hoping for 2-3 million to top line but with the spending out of control at present, probably no change to earnings. It will take 1 year till approval and then a further 2 years to negotiate pricing (longer if Lachlan has anything to do with it).
Clinuvel were probably better off staying with status quo and treating under special access. As they have elected to do in Switzerland, where they have never applied to swissmedic. Despite telling shareholders that they were going to.
Ann: Canadian New Drug Submission for SCENESSE in EPP filed, page-6
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.63 |
Change
0.120(0.89%) |
Mkt cap ! $682.3M | |||
| Open | High | Low | Value | Volume |
| $13.55 | $13.77 | $13.43 | $581.2K | 42.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 248 | $13.62 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.64 | 1 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| CUV (ASX) Chart |